José Baselga

Hebron University — PS

Medicine · Health Sciences

143h-index116.7kcitations1.4kworks0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(404), PI3K/AKT/mTOR signaling in cancer(320), Advanced Breast Cancer Therapies(264), Cancer Treatment and Pharmacology(214), Lung Cancer Treatments and Mutations(201)

Publications1.4k total

Supplementary File 1 from Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
2023Open Access
Supplementary Figure 4 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
2023Open Access
Supplementary Figures 1-10, Tables 1-2 from BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
2023Open Access
Supplementary Figure 1 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
2023Open Access
Supplementary Figure 2 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
2023Open Access
Interview with Dr. Engelman from BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
2023Open Access
Supplementary Figure 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
2023Open Access
Data from Accelerating Discovery of Functional Mutant Alleles in Cancer
2023Open Access
Supplementary Figure 3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Data from Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i><sup>V600</sup>-Mutant Non-Melanoma Cancers
2023Open Access
Supplementary Figure 1 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
2023Open Access
Data from Prospective Blinded Study of <i>BRAF</i><sup>V600E</sup> Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
2023Open Access
Supplementary Figure S4 from Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling
2023Open Access
Supplementary Data from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
2023Open Access
Table S1-4 from Accelerating Discovery of Functional Mutant Alleles in Cancer
2023Open Access
Data from Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
2023Open Access
Data from Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
2023Open Access
Supplementary Figure S1 from Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling
2023Open Access
Supplementary Tables 1 through 4 and Supplementary Figures 1 through 7 from Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure S1 from Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
2023Open Access
page 1 of 69Next →

Frequent Co-authors

Michael F. Berger(14), David B. Solit(14), Martine Piccart(13), David M. Hyman(13), Ahmet Zehir(10), Marc Ladanyi(9), Semiglazov Vf(8), Barry S. Taylor(8), Aron Goldhirsch(7), Richard D. Gelber(7), Michael Untch(6), Ian Smith(6), Mark E. Robson(6), Nikolaus Schultz(6), Mario Campone(6), Maurizio Scaltriti(6), Luca Gianni(5), David Cameron(5), Gopa Iyer(5), Gregory J. Riely(5)